Genetic studies reveal an unexpected negative regulatory role for jak2 in thrombopoiesis

Sara C. Meyer, Matthew D. Keller, Brittany A. Woods, Lindsay M. Lafave, Lennart Bastian, Maria Kleppe, Neha Bhagwat, Sachie Marubayashi, Ross L. Levine

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


JAK inhibitor treatment is limited by the variable development of anemia and thrombocytopenia thought to be due to on-target JAK2 inhibition. We evaluated the impact of Jak2 deletion in platelets (PLTs) and megakaryocytes (MKs) on blood counts, stem/ progenitor cells, and Jak-Stat signaling. Pf4-Cre-mediated Jak2 deletion in PLTsandMKs did not compromise PLT formation but caused thrombocytosis, and resulted in expansion ofMKprogenitors and Lin2Sca11Kit1 cells. Serum thrombopoietin (TPO) wasmaintained at normal levels in Pf4-Cre-positive Jak2f/f mice, consistent with reduced internalization/ turnover by Jak2-deficient PLTs. These data demonstrate that Jak2 in terminal megakaryopoiesis is not required for PLT production, and that Jak2 loss in PLTs and MKs results in non-autonomous expansion of stem/progenitors and of MKs and PLTs via dysregulated TPO turnover. This suggests that the thrombocytopenia frequently seen with JAK inhibitor treatment is not due to JAK2 inhibition in PLTs and MKs, but rather due to JAK2 inhibition in stem/progenitor cells. (Blood. 2014;124(14):2280-2284).

Original languageEnglish (US)
Pages (from-to)2280-2284
Number of pages5
Issue number14
StatePublished - Oct 2 2014
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Genetic studies reveal an unexpected negative regulatory role for jak2 in thrombopoiesis'. Together they form a unique fingerprint.

Cite this